Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …

The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in
the past few years, driven largely by translational research into its genomic landscape and …

Mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) are among the most
common aberrations in cancer, including non-small cell lung cancer (NSCLC). The lack of …

Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy
characterized by excessive proliferation and accumulation of immature myeloid blasts in the …

Some genetic abnormalities of multiple myeloma (MM) detected more than two decades ago
remain major prognostic factors. In recent years, the introduction of cutting-edge genomic …

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy in terms of
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …

Simple Summary The bone marrow (BM) microenvironment plays a crucial role in
pathogenesis of multiple myeloma (MM), and delineation of the intracellular signaling …

Abstract PI3K/AKT signaling is known to regulate cancer metabolism, but whether metabolic
feedback regulates the PI3K/AKT pathway is unclear. Here, we demonstrate the important …

Using a panel of cancer cell lines, we characterized a novel degrader of AKT, MS21. In
mutant PI3K–PTEN pathway cell lines, AKT degradation was superior to AKT kinase …

The serine/threonine kinase Akt is a major player in the phosphoinositide 3-kinase
(PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway, and its modulation …